| Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235 | Technology appraisal guidance | TBC |
| Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480] | Technology appraisal guidance | |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | Technology appraisal guidance | TBC |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | NICE guideline | TBC |
| Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073] | Technology appraisal guidance | |
| Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer
[ID6490] | Technology appraisal guidance | TBC |
| Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168] | Technology appraisal guidance | |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NICE guideline | TBC |
| Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 | Technology appraisal guidance | TBC |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | TBC |
| Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240] | Technology appraisal guidance | TBC |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Technology appraisal guidance | TBC |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma | Interventional procedures guidance | TBC |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] | Technology appraisal guidance | TBC |
| Epilepsies in children, young people and adults (extraordinary review) | NICE guideline | TBC |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920 | Technology appraisal guidance | TBC |
| Ex-situ machine perfusion devices for liver transplants: early value assessment | Health technology evaluation | |
| Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests | Diagnostics guidance | TBC |
| Familial Breast Cancer: initial assessment and genetic testing (update) | NICE guideline | |
| Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393] | Technology appraisal guidance | TBC |